CHIPSA Hospital 2020 Mid Year Cancer Treatment Review
2020 caught the entire world off guard. CHIPSA started off 2020 with big plans for treatment innovations for patients without any good options in their home country. But when covid-19 happened it tested our institutions resolve. And we are proud to say that we stayed the course against all odds and are now delivering high level cancer care better than ever before.
One thing that we would like to remind everyone with stage 4 cancer is that Cancer is likely to kill you long before Covid-19. We have seen so many patients die of their cancer because they were too afraid to get treated because of Covid-19. It’s truly insanity brought on by the mass manipulation of the media pumping fear over faith. We have long said that more patients will die of the unintended consequences of shutting everything down than Covid-19. That seems to be happening RIGHT before our eyes.
The CHIPSA Approach™has been a simple one: forget our ego and preconceived notions of what works in treating cancer, and be open to all possibilities. This includes considering both natural and man-made medications for the treatment of what is now considered incurable stage 4 cancer.
This approach is different from what has been used in the past. Our experience tells us that the non patented, alternative and patented conventional sides of medicine have long been at odds with each other regarding what is the best treatment.(We are seeing this with Covid-19 now) Each side casts giant stones at the other, all while millions of people are dying of cancer every year.
When CHIPSA Hospital reopened in August of 2015 after being closed for two years, it reopened with part of the old staff, many of whom worked with the legendary pioneer Charlotte Gerson. But it also reopened with a new group of doctors and scientists who are passionate about evolving alongside the latest scientific developments to fight this disease. CHIPSA has used nearly every natural method that’s known, and the fact is, in many cases, it simply is not enough. That’s not to say we haven’t seen amazing results in patients who adhere to natural therapies, but we simply aren’t satisfied with those results alone.
In January of 2017, we hired an award-winning oncologist from MD Anderson. This was an unprecedented move for a Mexican hospital, and one that drew harsh words from critics of anything conventional. But this move signaled a change of tide in our relentless pursuit to offer the best treatments possible for our patients. This U.S. oncologist was open to alternatives to the status quo as well as drastically lowering the doses of chemotherapy while mixing it with insulin. He has seen the devastation of high doses of chemotherapy destroying patient’s immune system, and after 30+ years, he has had enough.
The great start to 2017 gave us the momentum to further our research on Apatone. Apatone is a combination with the amazing potential to increase the effectiveness of chemotherapy without toxic side effects. A supplement that in some studies has shown to increase the potency of chemotherapy by over 600%. A product that had a phase 1 FDA trial in 2006 showing great promise, but lack of funds kept it from going through the ‘billion dollar’ FDA clinical trial process for market approval.
We are proud to say that after 16 months of work and research at CHIPSA, in November of 2017, Mexican based distributor UnoMedica got Apatone approved in Mexico as a supplement. As of the last week of December 2017, Apatone is available to patients all over the world who want to use it as a supplement with or without chemotherapy.
As we were supporting the development of Apatone, we were also able to see the true potential and promise of Mexico. Building a bridge to one U.S. oncologist and a small group of scientists working on Apatone was a start, but to make great gains, we knew we needed to form great alliances. We believe in a bigger vision. We aim to align our hospital in Mexico with some of the top scientists in the world, fast tracking research and embodying the very meaning of translational medicine.
More Treatments Available To Patients
In March 2019, CHIPSA ended its trial with Vallovax, treating 250 patients at no cost to them. This trial would have cost around 25+ million dollars in the United States, but we were able to do it at cost, which was approximately $750,000. CHIPSA covered the cost of the investigational medication for all patients starting in November 2017!
The success of our Vallovax trial led us to another company and their cancer treatment device that received breakthrough status by the FDA. While CHIPSA was the first to host the pre-clinical trial of Immunopheresis, that work is now being pursued in Europe and Israel. CHIPSA finished our portion of the trial at the end of 2019 and we are excited to see the work continue all over the world.
CHIPSA’s Personalized Cellular Therapy Program
The current groundbreaking research in immunotherapy that is thriving around the world has allowed us to gain new insights on how our treatments work with other treatments. One very popular treatment is called CPG. There are multiple ongoing trials, and each treatment works slightly different. This encouraged us to make our new batch of Coley’s with a focus on CPG.
In June of 2020 we started exclusively using our new Coley’s CPG therapy. Our new Coley’s CPG is made of the strongest stimulator of the innate immune system that we have seen. We have taken data and experience from our 22 years of experience with Coley’s fluid, and currently have the best balance of ingredients to maximize tumor cell death and increase the immune response.
We are also excited to announce our new dendritic cell therapy, DC-Max! In 2011, Provenge was approved by the U.S. FDA. This was the first dendritic cell therapy to make it through the FDA process. This product costs $94,000 for a 3 week treatment and is out of the price range for most patients. CHIPSA is able to offer dendritic cell treatments to patients for a fraction of the cost .
Scientists mature these dendritic cells and re-infuse them into the patient. This process, in conjunction with a danger signal in the cancer cell, provides a great opportunity for the dendritic cell to present the tumor antigen to the t-cell and get a lasting remission.
In conjunction with the dendritic cell therapy, we are also adding a whole tumor cell therapy called TL-Max. This drug is made from the patient’s individual tumor. This style of lysed therapy is undergoing multiple FDA trials and is showing promise. A small piece of a patient’s tumor is taken out along with a blood draw. The laboratory then takes the material and trains the immune system through the blood work to recognize the tumor antigen. This is made into a drug that allows the immune system to recognize the tumor antigen, thus attacking the cancer cells in the body. We expect a similar technology to be approved in the US in approximately 10 years.
VG-5000 builds upon the work of the acclaimed Russian immunologist Dr. Valentine Govallo. Author of 294 scientific papers and 19 scientific books, Dr. Govallo had over 40 years of experience in clinical immunology. His drug was derived from full-term donated placentas, which are normally thrown away after birth. He noticed that the immune system didn’t attack a placenta as it was being formed and later hypothesized that it would have the same defense mechanisms as a tumor.
In the 1970s, he treated 35 patients with various solid tumor carcinomas (lung cancer, breast cancer, colorectal, melanoma) and reported a 65% 10-year survival rate. Later generations of the therapy were made and used in different parts of the world, and recently, other companies have made similar therapies and defended mechanisms of action. VG-5000 stands for what is the 5th generation and most scientifically studied version of his treatment.
Another field of study that’s thriving right now in the United States is natural killer cell products. While we are several years away from approval in the United States, CHIPSA is taking the technology that is being studied and turning it into a proprietary product that can support the patient’s immune system into destroying cancer cells. This product is called NK-Max!
Natural Killer (NK) cells are the immune system’s first defense against disease and infection. NK cells have an amazing ability to seek out and destroy cancer cells. Our goal is to maximize the effects of the NK Cell therapy by using it in combination with our whole body approach.
We take a small blood draw and use the patient’s own NK cells in the lab. Once these cells are trained and expanded, we give them back to the patient with a large army of NK cells ready to fight cancer. Our personalized NK cell therapy is designed to produce a powerful and consistent immune response against cancer.
We have also added a AP-Max peptide therapy to our protocol. This drug takes two weeks to make and is made from the patient’s blood. Peptides are added and the immune system is primed to create the best possible immune response to the therapy.
Finally, we have added a little-known FDA-approved immune stimulator called GM-CSF. This differs from G-CSF, as studies show G-CSF tolerates dendritic cells and GM-CSF does not. GMCSF is very difficult to get in the United States, and most oncologists are not familiar with the science, so it is rarely used.
Combining These Treatments with Our Protocols
The immune effector response lasts 10-14 days. Once cancer is formed, it can no longer be seen by the immune system unless there is a signal. Dr. Polly Matzinger proposed the danger model as a way to explain how cancer interacts with the immune system. Using her model, we know that treatment modalities suggesting the clearing of cancer without a danger signal are not being truthful. This is why we use two cytotoxic agents. IPT and Apatone create a danger signal that alerts the immune system to the formation of cancer.
We then use our immune-stimulating treatments that are only available at CHIPSA. These treatments include Coley’s CPG, DC-MAX, and AP-Max. Our goal is to cause damage and danger to the cancer cell to maximize the use of our antigen-presenting cells (dendritic cells). When the antigen-presenting cell presents the last tumor antigen to the cytotoxic T cell, patients have the opportunity for a lasting remission due to the memory of the T cell.
This year, we hired more nutritionists on our team to start studying how much of the Gerson therapy patients can do. This study has allowed us to make adjustments and personalize the therapy for every patient.
We believe diet and detox is an integral part of our therapy, and many people use Gerson therapy as a standalone treatment. While we are the original Gerson hospital, we don’t look at the therapy as a standalone for cancer treatment.
Instead, we view it as an amazing adjunct diet for cancer patients that supports the immune system and floods the body with phytochemicals and nutrients.
Our knowledge is gaining traction and momentum everyday, and we will take every bit of our experience to bring the best treatments we can to our patients.
We are open and ready to treat everyone that needs our help. Don’t let fear keep you away.